Physician profile
Jonathon S Stillman
NPI 1174649289
$6,424.53
in general payments reported to CMS, 2019-2025
31 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $397 · 2021: $877 · 2022: $828 · 2023: $1,006 · 2024: $1,484 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Education: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.78 |
| Education | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.77 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,305.13 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $669.42 | 2019-2025 | Stelara, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $385.96 | 2019-2024 | Dificid, Zinplava |
| Takeda Pharmaceuticals U.S.A., INC. | $357.06 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $353.86 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $347.51 | 2024-2025 | Zenpep |
| Pfizer INC. | $252.25 | 2019-2025 | |
| Ardelyx, INC. | $215.58 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $154.45 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $102.11 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $98.96 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $91.54 | 2019-2022 | |
| Celltrion USA INC. | $87.07 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $86.35 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $71.98 | 2021-2025 | |
| Braintree Laboratories, INC. | $67.58 | 2019-2025 | Suflave |
| Qol Medical, LLC | $65.95 | 2021-2024 | Sucraid |
| Novo Nordisk INC | $50.14 | 2025 | Wegovy |
| Capsovision, INC. | $45.60 | 2024 | Capsocam Plus |
| Exact Sciences Corporation | $39.75 | 2023-2025 | Cologuard Collection Kit |
| Blueprint Medicines Corporation | $35.17 | 2024-2025 | Ayvakit |
| Madrigal Pharmaceuticals | $29.19 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $25.13 | 2022 | |
| Redhill Biopharma INC. | $23.77 | 2021 | |
| Biocon Biologics INC | $19.79 | 2025 | Yesintek |
| W. L. Gore & Associates, INC. | $19.18 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $17.91 | 2024 | Kristalose |
| Alnylam Pharmaceuticals INC. | $17.16 | 2020 | |
| Genzyme Corporation | $15.56 | 2022 | |
| Daiichi Sankyo INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Stillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.